In February 2025, InvestingPro's Fair Value analysis flagged Prestige Consumer Healthcare Inc. (NYSE:PBH) as overvalued when shares traded at $86.12. The platform's models put Fair Value at $50.69, roughly 41% below the market price. By the report's account, the stock later fell to a low of $45.64, a 46% decline from the flagged level. On the surface, that looks like a clean win for the tool.

The report's own numbers complicate that story. The stock's drop tracked a business that weakened in the same period. Revenue rose modestly to $1.17 billion, but EBITDA fell to $345 million from $361 million, and earnings per share dropped to $3.26 from $4.30, a 24% decline. The report also notes supply chain problems, and Jefferies cut its price target to $51, citing uncertainty around the Clear Eyes product line. When a share price falls alongside earnings, the market is doing its own valuation work, and a model that lands near the eventual low has not shown that its method was the reason.

A single prediction that matches a later price is weak evidence. The report does not describe how often InvestingPro's overvaluation flags have been right or wrong across other stocks, and it does not show the flag's timing relative to the price path, such as whether the stock kept rising for months before turning. Without that record, readers cannot tell skill from a lucky call on one name. The report also says the platform 'validated' its analysis, but a 46% decline is a result, not proof of method.

Investors should treat Fair Value estimates as one input among several. The report itself describes the methodology as blending discounted cash flow models, comparable company analysis, and analyst targets, which means the output depends on assumptions about future earnings that can change quickly, as the Prestige numbers show. A sensible next step for readers is to check the company's own filings and the analyst notes the report cites, then decide whether the drop reflects the deterioration described.

The marketing at the end of the report deserves skepticism. A promotional push for subscriptions and alerts is not the same as a record of performance, and the piece offers no independent track record to support the claim that the tool helps investors avoid losses. Prestige's decline is worth studying. It should not be sold as a template for buying a subscription.